CytoSorbents' Q2 Revenue Stalled-Can Better Margins and DrugSorb Progress Save the Story?

Flat revenue met better margins in Q2

Cytosorbents' second quarter came down to a familiar tension: can better economics offset stagnant demand? The short-term concern for CTSO investors is cash use versus cost improvement. The company reported second-quarter cash burn of about $0.4 million and said total cash, cash equivalents, and restricted cash was approximately $5.9 million at June 30, 2026 cash burn reduced to $0.4 millionTotal cash, cash equivalents, and restricted cash was approximately $5.9 million on June 30, 2026. If revenue stays flat, those balance-sheet gains matter more.

Revenue was essentially unchanged year over year, at about $9.6 million revenue essentially flat versus a year earlier. But the cost side improved. Gross margin rose to 73%, the operating loss narrowed 27% to $2.6 million, and adjusted net loss improved to $2.8 million from $3.7 million a year earlier Gross margin improved to 73%Operating loss improved by 27% to $2.6 millionAdjusted net loss... improved by 22% to $2.8 million. The GAAP net loss of $4.4 million was affected by foreign-currency translation items, which is why adjusted figures are the cleaner read for operating progress foreign-currency effects pushed the company to a $4.4 million GAAP net loss.

Why better economics matter

If Cytosorbents can keep reducing losses while preserving product quality and commercial effectiveness, the business has more time to prove the demand story. Better unit economics do not replace sales growth, but they do reduce pressure on the company while management tries to rebuild it.

Manufacturing gains are real, but demand is still the missing piece

Under the surface, Q2 looked better than the top line alone would suggest. When revenue held at $9.63 million, gross profit still rose about 3.4% and gross margin improved by two percentage points Gross profit increased... approximately +3.4%Gross margin... +2 percentage points.

Management also highlighted lower selling, general and administrative expense as part of the operating improvement lower selling, general and administrative expense helped reduce the operating loss. That fits the picture investors need to track: manufacturing optimization, sourcing improvements, and production efficiencies helped the company earn more on each unit sold while spending less to run the business.

The demand question remains unresolved

That improvement is encouraging, but it does not settle the bigger commercial question. A medical-device company can absorb a weak quarter without demand, but it usually cannot sustain that for long. So the real split in the road is simple:

• Bull case: margin improvement and lower cash burn buy time for the commercial base to recover.
• Bear case: revenue remains stuck, which would make cost cuts look more like damage control than a durable turnaround.

The quarter supports the first view more than the last one, but only future revenue trends can resolve it fully.

DrugSorb and regulatory status still shape the longer-term setup

Any reading of this quarter also has to keep regulatory context in view. CytoSorbents says CytoSorb is CE-marked in the EU, while CytoSorb and DrugSorb-ATR are investigational devices in the U.S. and are not yet FDA authorized, approved, or cleared CytoSorbents Corporation (NASDAQ: CTSO)... CytoSorb® and DrugSorb-ATR® are investigational devices not yet FDA authorized/approved/cleared.

That matters because it keeps the longer-term upside tied to future approvals or expanded indications, while the near-term story remains focused on margins, cash preservation, and core-market demand recovery.